Zhejiang Jianfeng Group

Zhejiang Jianfeng Group is a China-based listed company with a dual-core business structure spanning pharmaceuticals and building materials, with pharmaceuticals operated primarily through its subsidiary Zhejiang Jianfeng Pharmaceutical. In healthcare, the company manufactures and markets finished drugs, APIs, excipients, packaging materials, and health products, and it has a portfolio that includes ophthalmology products, anti-infectives, cardiovascular drugs, CNS products, and other generics. Jianfeng also maintains an innovation-oriented biotech arm, Zhejiang Jianfeng Yien Biotechnology, which is advancing JFAN-1001, an EGFR-targeted small-molecule program for non-small cell lung cancer. The group therefore combines a commercial generic pharma base with selected innovative oncology R&D. It is publicly traded in China and appears to remain an active operating company.